Merck has reported to the Food and Drug Administration (FDA) that all Liptruzet (ezetimibe/atorvastatin) tablets have been discontinued.

All lots of Liptruzet were initially recalled in January 2014 after defective outer laminate foil pouches were discovered. The foil pouches could potentially allow air and moisture inside the packaging, which would alter the effectiveness or characteristics of Liptruzet. Following the recall, Merck has decided to not resupply Liptruzet.

RELATED: Liptruzet Recall Will Likely Deplete Supply

Liptruzet is a combination cholesterol absorption inhibitor and HMG-CoA reductase inhibitor used in primary or mixed hyperlipidemia, and in homozygous familial hypercholesterolemia. It was available as 10mg/10mg, 10mg/20mg, 10mg/40mg, and 10mg/80mg in 30- and 90-count blister cards.

Merck noted this decision was business-related and not due to any safety or efficacy findings with Liptruzet.

For more information call (800) 672-6372 or visit